ALK is altered in 2.65% of peripheral T-cell lymphoma, not otherwise specified patients [2].

ALK is an inclusion eligibility criterion in 2 clinical trials for peripheral T-cell lymphoma, not otherwise specified, of which 2 are open and 0 are closed. Of the trials that contain ALK status and peripheral T-cell lymphoma, not otherwise specified as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].

BIRC2 is an inclusion eligibility criterion in 1 clinical trial for peripheral T-cell lymphoma, not otherwise specified, of which 1 is open and 0 are closed. Of the trial that contains BIRC2 status and peripheral T-cell lymphoma, not otherwise specified as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

BIRC3 is altered in 2.02% of peripheral T-cell lymphoma, not otherwise specified patients [2].

BIRC3 is an inclusion eligibility criterion in 1 clinical trial for peripheral T-cell lymphoma, not otherwise specified, of which 1 is open and 0 are closed. Of the trial that contains BIRC3 status and peripheral T-cell lymphoma, not otherwise specified as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

CARD11 is altered in 2.65% of peripheral T-cell lymphoma, not otherwise specified patients [2].

CARD11 is an inclusion eligibility criterion in 1 clinical trial for peripheral T-cell lymphoma, not otherwise specified, of which 1 is open and 0 are closed. Of the trial that contains CARD11 status and peripheral T-cell lymphoma, not otherwise specified as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

CD79A is altered in 1.1% of peripheral T-cell lymphoma, not otherwise specified patients [2].

CD79A is an inclusion eligibility criterion in 1 clinical trial for peripheral T-cell lymphoma, not otherwise specified, of which 1 is open and 0 are closed. Of the trial that contains CD79A status and peripheral T-cell lymphoma, not otherwise specified as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

CD79B is an inclusion eligibility criterion in 1 clinical trial for peripheral T-cell lymphoma, not otherwise specified, of which 1 is open and 0 are closed. Of the trial that contains CD79B status and peripheral T-cell lymphoma, not otherwise specified as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

NFKBIA is an inclusion eligibility criterion in 1 clinical trial for peripheral T-cell lymphoma, not otherwise specified, of which 1 is open and 0 are closed. Of the trial that contains NFKBIA status and peripheral T-cell lymphoma, not otherwise specified as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

TNFAIP3 is altered in 2.65% of peripheral T-cell lymphoma, not otherwise specified patients [2].

TNFAIP3 is an inclusion eligibility criterion in 1 clinical trial for peripheral T-cell lymphoma, not otherwise specified, of which 1 is open and 0 are closed. Of the trial that contains TNFAIP3 status and peripheral T-cell lymphoma, not otherwise specified as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].